{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:09Z","timestamp":1790402409100,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1124\/dmd.110.032326","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T03:04:34Z","timestamp":1274151874000},"page":"1328-1340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients"],"prefix":"10.1016","volume":"38","author":[{"given":"Aishen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.032326_bib1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/rcm.2996","article-title":"MSE with mass defect filtering for in vitro and in vivo metabolite identification","volume":"21","author":"Bateman","year":"2007","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.110.032326_bib2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1124\/dmd.110.032326_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032326_bib4","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.110.032326_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0090-9556(24)02980-5","article-title":"Selective reduction of N-oxides to amines: application to drug metabolism","volume":"32","author":"Kulanthaivel","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032326_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jms.1002","article-title":"Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography\u2013triple-quadrupole and linear ion trap mass spectrometers","volume":"41","author":"Marull","year":"2006","journal-title":"J Mass Spectrom"},{"key":"10.1124\/dmd.110.032326_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/dmd.110.032326_bib8","first-page":"13S","article-title":"Cancer treatment in the STI571 era: what will change?","volume":"19","author":"Sawyers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.110.032326_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0003-2697(84)90795-4","article-title":"The reduction of aliphatic and aromatic N-oxides to the corresponding amines with titanium(III) chloride","volume":"138","author":"Seaton","year":"1984","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.110.032326_bib10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"#cr-split#-10.1124\/dmd.110.032326_bib11.1","unstructured":"Sun PY, Lv AF, Hu CY, Wang WB (2008) inventors"},{"key":"#cr-split#-10.1124\/dmd.110.032326_bib11.2","unstructured":"Morris, Manning & Martin, LLP, assignee. Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof. U.S. patent 0,312,251, 2008 Dec 28."},{"key":"10.1124\/dmd.110.032326_bib12","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/rcm.3585","article-title":"Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection","volume":"22","author":"Zhang","year":"2008","journal-title":"Rapid Commun Mass Spectrom"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.032326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:43:17Z","timestamp":1739896997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0090955624024346"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.032326","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.032326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}